Article

Press Release

Study Finds Large Gap in Breast Cancer Treatment Recommendations for Patients Aged 70 vs 69

Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.

Suzanne B. Evans, MD, MPH, FASTRO

Suzanne B. Evans, MD, MPH, FASTRO

Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.

Radiation therapy often is given after breast-conserving surgery to help prevent a patient’s cancer from returning. While post-surgical radiation may be omitted for certain patients with early-stage breast cancer – including older patients with lower-risk disease – it remains standard-of-care for patients with a higher risk of cancer recurrence. In this analysis of nationwide data, however, researchers found that patients in this higher-risk subset who were age 70 at the time of diagnosis “were nearly twice as likely to be passed over for radiation1” as those age 69.

Patients diagnosed at age 70 were 53% less likely to be recommended post-operative radiation and 39% less likely to receive it, compared to patients age 69. There were no similar gaps between other year-over-year age groups (68 vs 69, 70 vs 71, etc.). The study, which is published in the International Journal of Radiation Oncology•Biology•Physics, is among “the first to demonstrate an age cutoff heuristic in oncology.”

“Our findings suggest that cognitive heuristics, or ‘rules of thumb,’ play a greater role in physician decision-making than we previously realized. It’s important that we center individual patients, with the unique characteristics of their cancer, as well as their individual preferences, in treatment decisions,” said Suzanne B. Evans, MD, MPH, FASTRO, senior author of the study and a professor of therapeutic radiology at Yale Cancer Center.

“While we would expect recommendations for this treatment to decline gradually as expected lifespan shortens, there seems to be a steep cliff when a patient moves from their 60s to their 70s. In breast oncology, physicians seem to anchor on a patient entering their 70s as a signal to de-escalate care, even in situations where evidence does not support this practice,” said Wesley J. Talcott, MD, MBA, lead author of the study and a radiation oncologist with Northwell Health. “Our study indicates that physicians should be mindful of how we factor age into treatment decisions and adopt a more nuanced approach, extending beyond defining patients as simply ’young’ or ’elderly.’”

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity